Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?

On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion.

Tevogen Bio stock is trading higher with a strong session volume of 62.2 million compared to the average volume of 5.8 million as per data from Benzinga Pro.

“This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a ...